[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362128-105":59,"doc-detail-362128-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-non-germ-cell-tumours-of-the-testis-focus-on-new-molecular-developments-in-sex-cord-stromal-tumours","Advances in non-germ cell tumours of the testis - focus on new molecular developments in sex cord-stromal tumours","","Testicular sex cord-stromal tumours (TSCSTs) account for approximately 4%–8% of testicular neoplasms, most showing Leydig or Sertoli cell phenotypes and benign behaviour. A malignant minority (~5%–10%) poses major clinical challenges because these tumours are consistently unresponsive to chemo- and radiotherapy and clinicopathologic features poorly predict malignancy. This review synthesizes recent clinicopathologic and molecular advances, emphasizing molecular alterations and biomarkers for diagnosis, classification, and prognosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-non-germ-cell-tumours-of-the-testis-focus-on-new-molecular-developments-in-sex-cord-stromal-tumours/362128/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-non-germ-cell-tumours-of-the-testis-focus-on-new-molecular-developments-in-sex-cord-stromal-tumours/362128.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What proportion of testicular tumours are non-germ cell and where do TSCSTs fit in?","Question",{"text":112,"@type":113},"TSCSTs represent about 4%–8% of all testicular neoplasms, while more than 90% of testicular neoplasms overall are of germ cell origin (TGCTs).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are malignant TSCSTs difficult to manage clinically?",{"text":117,"@type":113},"A malignant subset (~5%–10%) is consistently unresponsive to chemo- and radiotherapy, and their clinicopathologic features are suboptimal predictors of malignant potential.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular focus and biomarkers does the review highlight?",{"text":121,"@type":113},"The review focuses on molecular alterations and biomarkers that can refine diagnosis, classification, and prognosis, and discusses marker specificity limitations such as commonly used ‘classic’ markers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362128,1790194431,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Histopathology 2026, 88, 230–251. DOI: 10.1111/his.70006  \nREVIEW  \nAdvances in non-germ cell tumours of the testis: focus on new molecular developments in sex cord-stromal tumours  \nJoo Lobo 1,2,3 & Andres M Acosta4  \n1Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P. CCC), R. Dr. Antnio Bernardino de Almeida, 2Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P. CCC), R. Dr. Antnio Bernardino de Almeida, 3Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal and 4Department of Pathology, Indiana University, Indianapolis, Indiana, USA  \nLobo J & Acosta A M  \n(2026) Histopathology 88, 230–251. [https://doi.org/10.1111/his.70006](https://doi.org/10.1111/his.70006)  \nAdvances in non-germ cell tumours of the testis: focus on new molecular developments in sex cord-stromal tumours  \nTesticular sex cord-stromal tumours (TSCSTs) represent ~4%–8% of all testicular neoplasms. Most showa Leydig or Sertoli cell phenotype and exhibit benign clinical behaviour. However, a subset of ~ 10% is malignant and clinically problematic, as TGCTs do not respond to systemic therapy. Classiﬁcation of TSCSTs has relied on morphology, with several entities being deﬁned based on their resemblance to more common ovarian counterparts (e.g. granulosa cell  \ntumours) . In recent years, multiple clinicopathologic and molecular studies have improved our understanding of the mechanisms that underlie pathogenesis and progression in TSCSTs, providing data that can be useful to reﬁne classiﬁcation and prognostication. In this review, we summarise the major recent advances in TSCSTs, focusing on molecular alterations and biomarkers relevant for diagnosis, classiﬁcation and prognosis.  \nKeywords: granulosa cell tumour, Leydig cell tumour, Sertoli cell tumour, sex cord stromal tumours, testicular cancer  \nIntroduction  \nThe testis proper is composed of several cell types (germ cells, Sertoli cells, Leydig cells, peritubular myoid cells, among others), all of which can give rise  \nto neoplasms.1 Germ cell tumours, the most common testicular neoplasms in all age groups, derive from germ cell precursors that originate in the extraembryonic mesoderm of the yolk sac.2 A smaller subset of  \nAddress for correspondence: Andres M Acosta, Department of Pathology, Indiana University, 350 W, 11th Street, Room 4080, Indianapolis, IN 46202, USA. e-mail: [anmaacos@iu.edu](anmaacos@iu.edu)  \nConﬂict of interest statement: No conﬂicts declared.  \nAbbreviations: ACTH, adrenocorticotropic hormone; FAP, familial adenomatous polyposis; GUPS, Genitourinary Pathology Society; ISUP, International Society of Urological Pathology; LCCSCT, large cell calcifying Sertoli cell tumour; LCT, Leydig cell tumour; MGST, myoid gonadal stromal tumour; NOS, not otherwise speciﬁed; PARP, poly(ADP-ribose) polymerase; TGCT, testicular germ cell tumour; TSCST, testicular sex cord-stromal tumour.  \n􀀁 2025 The Author(s) . Histopathology published by John Wiley & Sons Ltd.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nTesticular SCSTs 231  \ntesticular tumours arises from (or differentiates to) components of the testicular stroma or sex cord derivatives, which originate from the embryonic mesoderm and coelomic epithelium, respectively.3  \nThe low incidence of testicular neoplasms, which account for ~ 1% of newly diagnosed male cancers worldwide,4 creates challenges for proper classiﬁcation because exposure to them is limited in most pathology practices. 5,6 Given that more than 90% of testicular neoplasms are of germ cell origin (i.e., testicular germ cell tumours—TGCTs","cbCaika3n4l6wIAR","https://ap.wps.com/l/cbCaika3n4l6wIAR","pdf",5886618,22,"English","# Introduction\n## Testicular neoplasms and origin\n## Clinical behaviour of TSCSTs and challenges\n# Molecular basis and biomarkers\n## Classification and prognostication\n## Immunohistochemistry and marker relevance","[{\"question\":\"What proportion of testicular tumours are non-germ cell and where do TSCSTs fit in?\",\"answer\":\"TSCSTs represent about 4%–8% of all testicular neoplasms, while more than 90% of testicular neoplasms overall are of germ cell origin (TGCTs).\"},{\"question\":\"Why are malignant TSCSTs difficult to manage clinically?\",\"answer\":\"A malignant subset (~5%–10%) is consistently unresponsive to chemo- and radiotherapy, and their clinicopathologic features are suboptimal predictors of malignant potential.\"},{\"question\":\"Which molecular focus and biomarkers does the review highlight?\",\"answer\":\"The review focuses on molecular alterations and biomarkers that can refine diagnosis, classification, and prognosis, and discusses marker specificity limitations such as commonly used ‘classic’ markers.\"}]","Advances in non-germ cell tumours of the testis - focus on new molecular developments in sex cord-stromal tumours | PDF",1790146539,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27ec473573a4539ed14779a57a6a44f6.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/741c6ad2d6cc230e17b5e4b8b7a11fa5.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f5cb95920b04a71dd663236fc281c61.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f53b2d6415babdb716c2a982c7d9d59c.webp",980,1287]